Racial diversity in clinical trials serves as a metric of equality and access to healthcare. However, unfortunately, trial populations frequently do not represent populations they intend to emulate. Current International Committee of Medical Editors (ICJME) guidelines recommend as a minimum, descriptive data on race and ethnicity. Furthermore, US Food and Drug Administration (FDA) guidelines introduced in 2016 also recommend race should be reporting universally, as a minimum of 5 categories.